Cancer Research24 Dec 2019 11:10
All thoughts for victim's of Prostate cancer if Valrix can reach Phase 3 this year and find solution for million's around the world. Merry Xmas to all sufferer's who need cure, also for all investors who backed Val to find a solution in doing so they are out of pocket five figures and more, hope New Year Valrix finds a solution or a partner to carry all the research forward and reward the shareholder with results followed by Rerate of the SP...in the New Year wishing a Very Happy New year...with positive results 0f Val 201 and Val 401..
VAL201 has been developed in collaboration with Cancer Research (CRUK) and is a decapeptide with potential in treating hormone-dependent and hormone-independent prostate cancer, currently a poorly served multi-billion dollar commercial market.
"With prostate cancer reported this month in an academic study as being the most common cancer in men in the UK* and with an estimated 1.3 million new cases of prostate cancer occurring worldwide last year**, it is truly exciting to see VAL201 approaching the conclusion of its Phase I/II first-in-man study."